sorbitol has been researched along with baclofen in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bertrand, V; Boucard, A; Cholet, N; Chumakov, I; Cohen, D; Foucquier, J; Glibert, F; Graudens, E; Guedj, M; Hajj, R; Laffaire, J; Mandel, J; Milet, A; Nabirotchkin, S; Nave, KA; Pereira, Y; Primas, G; Sereda, MW; Vial, E | 1 |
| Al-Moussawi, M; Attarian, S; Bertrand, V; Bossi, L; Boudiaf, L; Chumakov, I; Cohen, D; Dubourg, O; Franques, J; Funalot, B; Ghorab, K; Gilbert, W; Gonnaud, PM; Guedj, M; Hajj, R; Lacour, A; Leclair-Visonneau, L; Lefebvre, MN; Lehert, P; Magot, A; Magy, L; Mandel, J; Micallef, J; Milet, A; Nabirotchkin, S; Péréon, Y; Pouget, J; Preudhomme, M; Scart-Grès, C; Stojkovic, T; Tiffreau, V; Vallat, JM | 1 |
| Kipping, T; Mishra, SM; Nukala, PK; Palekar, S; Patel, K | 1 |
| Adam, J; Cohen, D; Ewers, D; Hajj, R; Kungl, T; Mroczek, M; Nabirotchkin, S; Nave, KA; Prukop, T; Sereda, MW; Stenzel, J; Wernick, S | 1 |
| Adam, J; Barrantes-Freer, A; Bartl, M; Boussicault, L; Brureau, A; Cohen, D; Czesnik, D; Ewers, D; Hajj, R; Jäger, K; Laffaire, J; Linhoff, L; Nabirotchkin, S; Nave, KA; Primas, G; Prukop, T; Quintes, S; Rinaudo, P; Schmidt, J; Schwab, MH; Sereda, MW; Wernick, S; Winter, L; Zschüntzsch, J | 1 |
| Adams, D; Amato, A; Attarian, S; Brannagan, TH; Carter, G; Casanovas, C; de Visser, M; Felice, K; Magy, L; Péréon, Y; Statland, JM; Stino, A; Tard, C; Thomas, FP; Van Damme, P; Verhamme, C; Walk, D; Walter, MC; Young, P | 1 |
1 review(s) available for sorbitol and baclofen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for sorbitol and baclofen
| Article | Year |
|---|---|
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
Topics: Adult; Baclofen; Charcot-Marie-Tooth Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Sorbitol | 2014 |
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
Topics: Baclofen; Charcot-Marie-Tooth Disease; Double-Blind Method; Humans; Naltrexone; Sorbitol | 2021 |
5 other study(ies) available for sorbitol and baclofen
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Topics: Animals; Axons; Baclofen; Charcot-Marie-Tooth Disease; Coculture Techniques; Disease Models, Animal; Down-Regulation; Drug Repositioning; Drug Therapy, Combination; Female; Gene Expression Regulation; Male; Mice; Myelin Proteins; Naltrexone; Nerve Fibers, Myelinated; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Sciatic Neuropathy; Sorbitol | 2014 |
Application of 3D printing technology and quality by design approach for development of age-appropriate pediatric formulation of baclofen.
Topics: Age Factors; Baclofen; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Child; Drug Liberation; Excipients; Humans; Muscle Relaxants, Central; Polyvinyl Alcohol; Printing, Three-Dimensional; Sorbitol; Technology, Pharmaceutical; X-Ray Diffraction | 2019 |
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Topics: Animals; Axons; Baclofen; Charcot-Marie-Tooth Disease; Demyelinating Diseases; Disease Models, Animal; Drug Combinations; Male; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Muscle Weakness; Myelin Proteins; Naltrexone; Neural Conduction; Phosphatidylinositol 3-Kinases; Proof of Concept Study; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Schwann Cells; Signal Transduction; Sorbitol | 2019 |
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
Topics: Animals; Baclofen; Charcot-Marie-Tooth Disease; Coculture Techniques; Demyelinating Diseases; Drug Synergism; Drug Therapy, Combination; Female; Male; Myelin Proteins; Naltrexone; Neural Conduction; Neuromuscular Junction; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Sorbitol | 2020 |